Τόμος 23 (2005) – Τεύχος 3 – Άρθρο 7 – Επιθεώρηση Κλινικής Φαρμακολογίας και Φαρμακοκινητικής-Ελληνική Έκδοση – Volume 23 (2005) – Issue 3 – Article 7 – Epitheorese Klinikes Farmakologias και Farmakokinetikes-Greek Edition

Γκρέτα Βόζνιακ¹, Ευαγγελία Κοτρώσιου², Ζωή Ρούπα²

¹Τμήμα Πυρηνικής Ιατρικής, Περιφερειακό Πανεπιστημιακό Νοσοκομείο Λάρισας ² Τμήμα Νοσηλευτικής, Τεχνολογικό Εκπαιδευτικό Ίδρυμα  Λάρισας, Λάρισα, Ελλάς

G. Wozniak¹, E. Kotrotsiou², Z. Roupa³

¹Department of Nuclear Medicine, General Peripheral, University of Thessaly, Larissa, Hel­las, ² Nursing Department, Technological Educa­tional Institution of Larissa, Larissa, Hellas

2. Riccioni G., Di Llio C., D’Orazio N.: An uptake of the leukotriene modulators for the treatment of asthma. Ex­pert. Opin. Invest. Drugs 13: 763-776 (2004)

3. Tan R.A., Sheldon L. Spector S.L.: Antileukotriene agents. Opin. Pulm. Med. 3: 215-220 (1997)

4. Kellaway C.H., Trethewie E.R.: The liberation of a slow reacting smooth muscle stimulating substance in anaphy­laxis. J. Exp. Physiol. 30: 121-145 (1940)

5. Abe M., Yoshimoto T.: Leukotriene–lipoxygenase pathway and drug discovery. Nippon Yakurigaku Zasshi 124: 415-25 (2004)

6. Miller D.K., Gillard J.W., Vickers P.J., Sadowski S., Leveille C., Mancini J.A., et al. : Identification and isolation of a membrane protein necessary for leukotriene produc­tion. Nature 343: 278-281 (1990)

7. Borgeat P., Samuelsson B.: Metabolism of arachidonic acid in polymorphonuclear leukocytes. Structural analysis of novel hydroxylated compound. Biol. Chem. 254: 7865-7867 (1979)

8. Dixon R.A., Diehl R.E., Opas E., Rands E., Vickers P.J., Evans J.F., et al.: Requirement of a 5-lipoxygenase-acti­vating protein for leukotriene synthesis. Nature 343: 282-284 (1990)

9. Reid G.K., Kargman S., Vickers P.J., Mancini J.A., Leveille C., Ethier D., et al.: Correlation between expres­sion of 5-lipoxygenase-activating protein, 5-lipoxygenase, and cellular leukotriene synthesis. J. Biol. Chem. 265: 19818-19823 (1990)

10. Orning L., Kaijser L., Hammarstrom S.: In vivo me­tabolism of leukotriene C₄ in man: urinary excretion of leukotriene E₄. Biophys. Res. Comm. 130: 214-220 (1985)

11. Westcott J.Y., Johnston K., Batt R.A,, Wenzel S.E,, Voelkel N.F.: Measurement of peptidoleukotrienes in bio­logical fluids. Appl. Physiol. 68: 2640-2648 (1990)

12. Taylor G.W., Taylor I., Black P., et al.: Urinary leukot­riene E₄ after antigen challenge in acute asthma and aller­gic rhinitis. Lancet i: 584-588 (1989)

13. Christie P.E., Tagari P., Fordhutchinson A.W., et al.: Urinary leukotriene-E₄ concentrations increase after aspi­rin challenge in aspirin-sensitive ast atic subjects. Am. Rev. Respir. Dis. 143: 1025-1029 (1991)

14. Okubo T., Takahashi H., Sumitomo M., Shindoh K., Suzuki S.: Plasma levels Of leukotrienes C₄ and D₄ during wheezing attack in asthmatic patients. Arch. Allergy Appl. Immunol. 84: 149-55 (1987)

15. Heavey D.J., Soberman R.J., Lewis R.A., Spur B., Austen K.F.: Critical considerations in the development of an assay for sulfidopeptide leukotrienes in plasma. Prostaglandins 33: 693-708 (1987)

16. Wenzel S.E., Larsen G.L., Johnston K., Voelkel N.F., Westcott J.Y.: Elevated levels of leukotriene C₄ in bron­choalveolar lavage fluid from atopic asthmatics after endo­bronchial allergen challenge. Rev. Respir. Dis. 142: 112-119 (1990)

17. Wenzel S.E., Westcott J.Y., Larsen G.L.: Bronchoal­veolar lavage fluid mediator levels 5 minutes after allergen challenge in atopic subjects with asthma: relationship to the development of late asthmatic response. Allergy Clin. Immunol. 87: 540-548 (1991)

18. Israel E., Dermarkarian R., Rosenberg M., Sperling R., Taylor G., Rubin P., Drazen J.M.: The effects of a 5-li­poxygenase inhibitor on asthma induced by cold, dry air. Engl. J. Med. 323: 1740-1744 (1990)

19. Broide D.H., Eisman S., Ramsdell J.W., Ferguson P., Schwartz L.B., Wasserman S.I.: Airway levels of mast cell-derived mediators in exercise-induced asthma. Rev. Respir. Dis. 141: 563-568 (1990)

20. Sala A., Voelkel N., Maclouf J., Murphy R.C.: Leukot­riene E₄ elimination and metabolism in normal human subjects. Biol. Chem. 265: 21771-21778 (1990)

21. Samboun M.N., Conroy D.M., Piper P.J.: Pharma­cological profile of leukotriene E₄, N-acetyl E₄ and of four of their novel omega- and beta-oxidative metabolites in airways of guinea-pig and man in vitro. J. Pharmacol. 98: 1406-1412 (1989)

22. Miadonna A., Tedeschi A., Leggieri E., et al.: Behavior and clinical relevance of histamine and leukotrienes C₄ and B₄ in grass pollen-induced rhinitis. Am. Rev. Respir. Dis. 136: 357-362 (1987)

23. Adelroth E., Morris M.M., Hargreave F.E., O’Byrne P.M.: Airway responsiveness to leukotrienes C₄ and D₄ and to methacholine in patients with asthma and normal controls. Engl. J. Med. 315: 480-484 (1986)

24. Arm J.P., Spur B.W., Lee T.H.: The effects of inhaled leukotriene E₄ on the airway responsiveness to histamine in subjects with asthma and normal subjects. Allergy Clin. Immunol. 82: 654-656 (1988)

25. Diamant Z., Timmers M.C., Van der Veen H., Fried­man B.S., De Smet M., Depre M., et al.: The effect of MK-05917 a novel 5-lipoxygenase activating protein inhibitor, on leukotriene biosynthesis and allergen-induced airway responses in asthmatic subjects in vivo. J. Allergy Clin. Immunol. 95: 42-51 (1995)

26. Nayak A.: A review of montelukast in the treatment of asthma and allergic rhinitis. Opin. Pharmacother. 5: 679-686 (2004)

27. Weller P.F., Lee C.W., Foster D.W., Lorey E.J., Austen K.F., Lewis R.A.: Generation and metabolism of 5-lipoxy­genase pathway leukotrienes by human eosinophils: pre­dominant production of leukotriene C₄. Natl. Acad. Sci. USA 80: 7626-7630 (1983)

28. Friedman B.S., Bel E.H., Buntinx A., Tanaka W., Han Y.H., Shingo S., et al.: Oral leukotriene inhibitor (MK-886) blocks allergen-induced airway responses. Am. Rev. Res­pir. Dis. 147: 839-844 (1993)

29. Spector S.L.: Leukotriene inhibitors and antagonists in asthma. Allergy Asthma Immunol. 75: 463-474 (1995)

30. Knorr B., Matz J., Bernstein J.A., Nguyen I.T., Seiden­berg B.C., Reiss T.F., Becker A. (for the pediatric Montelu­kast Study Group). Montelukast for chronic asthma in 6 to 19 Year old children. JAMA 279(15): 1181-1186 (1998)

31. Reiss T.F., Chervinsky P., Dockhorn R.J., Shingo S., Seidenberg B., Edwards T.B. (for the Montelukast Clinical Research Study Group). Montelukast, a once-daily leukot­riene receptor antagonist, in the treatment of chronic asthma. A multicenter, randomized, double-blind trial. Intern. Med. 158: 1213-1220 (1998)

32. Bott A., DeLepeleire Rochette F.: MK-0476 causes prolonged, potent LTD₄ receptor antagonism in the airway of asthmatics. J. Respir. Crit. Care Med. 149: A465 (abstract) (1994)

33. O’Byrne P.M., Watson R.M., Strong H.A., Wylie G.: The effect of treatment with a 5-lipoxygenase inhibitor, BAYX1005 on allergen-induced asthmatic responses in human subjects. J. Respir. Crit. Care Med. 149: A532 (abstract) (1994)

34. Gaszczyk G., Latos T., Slowikowski A., Janiak B.: Single dose of montelukast as an effective prevention of post exercise bronchospasm in children with bronchical asthma. Wieku Rozwoj. VIII(3 Pt 2): 847-856 (2004)

35. Meitzer S.S., Cohli J., Bleech E.R., Hasday J.D.: Inhi­bition of exercise induced asthma by zileuton a 5-lipoxy­genase inhibitor. J. Respir. Crit. Care Med. 153: 931-935 (1996)

36. Israel E., Fischer A.R., Rosenberg M.A., Lilly G.M., Callery J.C., Shapiro J., Cohri J., Rubin P., Drazen J.M.: The pivotal role of 5-lipoxygenase products in the reaction of aspirin-sensitive asthmatics to aspirin. Rev. Respir. Dis. 148: 1447-1451 (1993)

37. Nasser S.M., Bell G.S., Foster S., Spruce K.E., Mac Millan R., Williams A.J., et al.: Effect of the 5-lipoxygenase inhibitor ZD2138 on aspirin-induced asthma. Thorax 49: 749-756 (1994)

38. Dahlen B., Margolskee D.J., Zetterstrom O., Dahlen S.E.: Effect of the leukotriene receptor antagonist MK-0679 on baseline pulmonary function in aspirin sensitive asthmatic subjects. Thorax 48: 1205-1210 (1993)

39. Calhoun W.J., Lavins B.J., Minkwitz M.C., Glass M.: Effects of Accolate^TM (zafirlukast) on bronchoalveolar lavage fluid (BAL) after segmental antigen bronchoprovo­cation (SBP) in patients with mild to moderate asthma. J. Respir. Crit. Care Med. 157: 1381-1839 (1998)

40. Suissa S., Dennis R., Ernst P., Sheehy O., Wood Dau­phinee S.: Effectiveness of the leukotriene receptor an­tagonist zafirlukast for mild to moderate asthma: a ran­domized, double-blind, placebo controlled trial. Intern. Med. 126: 177-183 (1997)

41. Wechsler M.E., Garpestad E., Flier S.R., et al.: Pulmo­nary infiltrates, eosinophilia and cardiomyopathy following corticosteroid withdrawal in patients with asthma receiving zarfirlukast. JAMA 279: 455-457 (1998)

42. Barnes N.: Replacing or reducing high-dose oral corti­costeroids with alternative asthma controller therapies: implications for leukotriene receptor antagonists. Respir. Rev. 8: 63, 1054-1055 (1998)

43. Dupont L., Potvin E., Korn D., Lachman A., Dramaix M., Gusman J., Peche R.: Improving asthma control in patients subotimally cotrolled on inhaled steroids and long-acting beta2-agonists: addition of montelukast in an open-label pilot study. Med. Res. Opin. 21: 863-870 (2005)

44. Ilowite J., Webb R., Friedman B., Kerwin E., Bird S.R., Hustad C.M., Edelman J.M.: Addition of montelukast or salmeterol to fluticasone for protection against asthma attacks: a randomized, double-blind, multicenter study. Allergy Asthma Immunol. 92: 641-648 (2004)

45. Josefson D.: Asthma drug linked with Churg-Strauss syndrome. Br. Med. 315: 330 (1997)

46. Liu M., Dube L.M., Lancaster J., Zileuton Study Group: Acute and chronic effects of a 5-lipoxygenase inhibitor in asthma: a 6-month randomized multicenter trial. J. Al–lergy Clin. Immunol. 98: 859-871 (1995)

47. Global Initiative for Asthma. Pocket guide for asthma management and prevention. NIH Publication No. 96-36598. National Institutes of Health, Bethesda, MD, 1998